LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a leading acute care therapeutics company, today provided an overview of selected studies that will be presented at the 49th Annual Infectious Diseases Society of America (IDSA) meeting taking place from October 20th to 23rd, 2011 in Boston. The studies focus on the company’s investigational antibiotic, CXA-201, as well as on patterns of first-line treatment for complicated skin and skin structure infections in U.S. hospitals.
